Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
However, the two have not been directly compared in a head-to-head trial, and retatrutide is not yet approved
Retatrutide is an investigational once-weekly injectable triple receptor agonist activating GLP-1, GIP, and glucagon receptors to reduce appetite, improve insulin secretion, and increase energy expenditure
Complete Support System : Meal plans, health tracking, and check-ins help make injections part of a larger lifestyle change
While the relative risk reduction tended to be largest with low CV risk score, the largest absolute risk reduction was for intermediate to high CV risk score
This article is for informational purposes only and does not substitute for professional medical advice
US$ 28.17
US$ 24.68
US$ 26.65
US$ 24.38
US$ 22.46
US$ 26.38
US$ 25.15
US$ 27.44
US$ 20.60
US$ 29.73
US$ 24.76
US$ 27.63
US$ 27.21
